Contribution of MEK/MAPK and PI3‐K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects
暂无分享,去创建一个
Piero Picci | Stefania Perdichizzi | P. Picci | K. Scotlandi | S. Perdichizzi | M. Serra | S. Benini | V. Cerisano | M. Manara | Massimo Serra | R. Strammiello | Maria Cristina Manara | Katia Scotlandi | Stefania Benini | Rosaria Strammiello | Vanessa Cerisano | Maria Cristina Manara
[1] D. Yee,et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. , 1990, The Journal of clinical investigation.
[2] J. Toretsky,et al. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. , 1999, Cancer research.
[3] L. Wang,et al. Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[4] F. Peruzzi,et al. Regulation of Id Gene Expression by Type I Insulin-Like Growth Factor: Roles of STAT3 and the Tyrosine 950 Residue of the Receptor , 2001, Molecular and Cellular Biology.
[5] P. Lollini,et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. , 1998, Cancer research.
[6] P. Lollini,et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. , 1996, Cancer research.
[7] D. Leroith,et al. The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts* , 1997, The Journal of Biological Chemistry.
[8] S. Aaronson,et al. Basis for the acquisition of malignant potential by mouse cells cultivated in vitro. , 1968, Science.
[9] B. Calabretta,et al. Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis , 1999, Molecular and Cellular Biology.
[10] P. Lollini,et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells , 2002, Cancer Gene Therapy.
[11] M. Karas,et al. Insulin-like Growth Factor-I (IGF-I) Receptor Activation Rescues UV-damaged Cells through a p38 Signaling Pathway , 2001, The Journal of Biological Chemistry.
[12] D. Leroith. Insulin-like growth factor I receptor signaling--overlapping or redundant pathways? , 2000, Endocrinology.
[13] L. Wang,et al. Stat5 is a physiological substrate of the insulin receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[14] D. Leroith,et al. Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis. , 1997, Endocrinology.
[15] Philip R. Cohen,et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1 , 1995, FEBS letters.
[16] J. Sebolt-Leopold. Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.
[17] S. Aaronson,et al. Basis for the Acquaisition of Malignant Potential by Mouse Cells Cultivated in vitro , 1968, Science.
[18] K Y Hui,et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.
[19] O. Larsson,et al. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells , 2000, Oncogene.
[20] G. Romano,et al. Dissociation between resistance to apoptosis and the transformed phenotype in IGF‐I receptor signaling , 1999, Journal of cellular biochemistry.
[21] P. Lollini,et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] D. Andrews,et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Klopp,et al. Application of balloon technique in detection of cancer , 1953, Cancer.
[24] Philip R. Cohen,et al. PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.
[25] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[26] D. Levy,et al. Mechanism of STAT3 Activation by Insulin-like Growth Factor I Receptor* , 2000, The Journal of Biological Chemistry.
[27] W. Winkelmann,et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Leroith,et al. Insulin-like Growth Factor I Induces MDM2-dependent Degradation of p53 via the p38 MAPK Pathway in Response to DNA Damage* , 2002, The Journal of Biological Chemistry.
[29] E. Feldman,et al. GTPases and phosphatidylinositol 3-kinase are critical for insulin-like growth factor-I-mediated Schwann cell motility. , 2000, The Journal of biological chemistry.
[30] R. Baserga. The contradictions of the insulin-like growth factor 1 receptor , 2000, Oncogene.
[31] D. Leroith. Editorial: Insulin-Like Growth Factor I Receptor Signaling-Overlapping or Redundant Pathways? , 2000, Endocrinology.
[32] J. Blenis,et al. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[33] M. Rubini,et al. The IGF-I receptor in cell growth, transformation and apoptosis. , 1997, Biochimica et biophysica acta.
[34] H. Kovar,et al. The Ewing family of tumors and the search for the Achilles' heel. , 1999, Current opinion in oncology.
[35] M. Campanacci. Bone and Soft Tissue Tumors , 1999, Springer Vienna.
[36] R. Souhami,et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] P. Sorensen,et al. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors , 2002, Oncogene.
[38] P. Lollini,et al. Expression of an IGF‐I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells , 2002, International journal of cancer.
[39] D. Leroith,et al. Insulin-like Growth Factor 1 Inhibits Apoptosis Using the Phosphatidylinositol 3′-Kinase and Mitogen-activated Protein Kinase Pathways* , 1997, The Journal of Biological Chemistry.
[40] R. Ilaria,et al. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation , 2000, Oncogene.
[41] J. Oh,et al. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. , 2001, Cancer research.
[42] F. Hobbs,et al. Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.
[43] L. Flechner,et al. Protein Kinase C-δ Is an Important Signaling Molecule in Insulin-Like Growth Factor I Receptor-Mediated Cell Transformation , 1998, Molecular and Cellular Biology.
[44] T. Triche,et al. The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.
[45] P. Picci,et al. The expression of ccn3(nov) gene in musculoskeletal tumors. , 2002, The American journal of pathology.
[46] R. Baserga,et al. Regulation of Id2 Gene Expression by the Insulin-like Growth Factor I Receptor Requires Signaling by Phosphatidylinositol 3-Kinase* , 2001, The Journal of Biological Chemistry.
[47] K. Nguyen,et al. Differential requirements of the MAP kinase and PI3 kinase signaling pathways in Src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells , 2000, Oncogene.
[48] S. Ferrari,et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone , 1998, Cancer.
[49] J. V. van Leeuwen,et al. Regulation of Osteocalcin Production and Bone Resorption by 1,25‐Dihydroxyvitamin D3 in Mouse Long Bones: Interaction with the Bone‐Derived Growth Factors TGF‐β and IGF‐I , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[50] T. MacDonald,et al. The Ewing tumor family of peripheral primitive neuroectodermal tumors expresses human gastrin-releasing peptide. , 1998, Cancer research.
[51] M. Ladanyi,et al. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. , 2000, The American journal of pathology.